Autoimmune Cytopenias

Using a search of drug labels on FDA.gov, a team of investigators from Israel conducted a meta-analysis of 6 randomized controlled trials (RCTs) supporting regulatory approval of several targeted therapies recently approved for second-line treatment of immune thrombocytopenia (ITP). The RCTs comprised a total of 752 patients. The team found that, compared with placebo, targeted therapies for ITP were associated with significantly lower odds for both major and minor bleeding as well as a trend towards lower mortality rates, without increased toxicity.